Moreover, given the role of receptors such as EGFR, c-Met and HER2 in activating signal transduction pathways, it is not surprising that activation of c-Cbl is also associated with reduced levels of Akt and NF-κB activity (Li et al, 2007), two additional targets of current cancer therapeutic strategies (see, e.g. De Luca et al, 2012; Morrow et al, 2011; Nogueira et al, 2011). This evidence concerns the gene EGFR and cancer.